Cardiovascular outcomes in type 1 and type 2 diabetes

Abstract

Diabetes is one of the most prevalent cardiometabolic disorders on the planet. Type 1 diabetes accounts for only a minority of all cases (recently estimated to be ~2% globally); however, since this is a disorder with an early onset, many people live with type 1 diabetes for a long time. CVD and premature death are the main long-term outcomes for both types of diabetes; however, the type of diabetes that carries the highest risk of these outcomes is a controversial topic and has not been widely studied. Because of the association between diabetes and CVD, the rise in type 2 diabetes prevalence over the past decades has huge effects on global health. The excess risk in people with diabetes compared with those without depends, to a large extent, on the presence of other factors, such as general cardiovascular risk factors (e.g. elevated LDL-cholesterol, hypertension and smoking) and also factors that are more specific to diabetes (e.g. HbA1c, and micro- and macroalbuminuria). Some contributory factors are modifiable, while others are not, such as age, sex and type of diabetes. Older people with type 2 diabetes who have risk factors that are under control can achieve levels of CVD risk that are similar to that of the general population, while younger individuals with type 1 diabetes are mostly unable to achieve similar levels of risk, probably because of long and cumulative exposure to raised blood glucose levels. Despite reports of declining rates of CVD among people with type 1 and type 2 diabetes, rising rates of both types of diabetes lead to a continuing rise in the number of people with cardiometabolic disorders worldwide, offsetting the progress made in many countries. Comparison between individuals with type 1 and type 2 diabetes with respect to risk of CVD is fraught with difficulties and highly dependent on other, concomitant factors, some of which are modifiable and others not. Nonetheless, as a whole, what matters most in determining the management of diabetes is absolute risk and lifetime risk. Life-long efforts to achieve glycaemic control, control of lipids and hypertension, and not smoking are key to prevention, with a healthy lifestyle and pharmacological therapy to be implemented as needed. Graphical abstract

Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach

“…3). Moreover, other IPF-related diseases found in this study such as Alzheimer's disease, obesity, cardiovascular diseases, systemic lupus erythematosus are linked to diabetes [35][36][37][38][39] . Furthermore, the two signaling nodes in the inter-organ mechanism of IPF proposed in our study (Fig.…”

Therapie des Typ-2-Diabetes

“…Es ist zu bedenken, dass mit steigendem Alter und zunehmender Schwere der Komorbiditäten die Wahrscheinlichkeit abnimmt, von einer zusätzlichen Intervention zu profitieren [1]. Der aktuell publizierte Review über Risikofaktoren für kardiovaskuläres Outcome bei Menschen mit Diabetes unterstreicht erneut eindrücklich die Bedeutung der therapierbaren klassischen Risikofaktoren wie Gewicht, HbA1c, Low-density-Lipoprotein (LDL)-Cholesterin, Blutdruck, Albuminurie und Rauchen [7]. Eine aktuelle Analyse zeigt, dass die derzeit zur Verfügung stehenden 22 kardiovaskulären Risiko-Scores für Menschen mit Typ-2-Diabetes unzureichend sind.…”

Evaluation of mulberry leaves’ hypoglycemic properties and hypoglycemic mechanisms

“…Diabetes mellitus (DM), a metabolic disorder that causes polyphagia, polydipsia, polyuria, and weight loss clinically, is characterized by an absolute or relative lack of insulin secretion and decreased sensitivity of target organs to insulin. It is estimated that by 2045, the number of people with diabetes will reach 783.2 million worldwide ( Rosengren and Dikaiou, 2023 ). A study from China shows that the number of people with diabetes in the country will reach 217.64 million by 2030 ( Sun et al, 2022 ).…”